- About Us
- Patient Resources
- Contact & Location
- My CS Link Web Portal
There’s a case for a new, breakthrough treatment for systemic lupus erythematosus, in the form of a new drug already approved in Europe.
Dr. Daniel J. Wallace recently presented his findings at the Annual European Congress of Rheumatology in Amsterdam.He found that 4mg of baricitinib resulted in significant clinical improvement, specifically in the case of fatigue and arthritis in his subjects.
“Baricitinib is a small molecule oral agent taken daily that works on cell surface receptor activation,” Wallace said. “This agent is already on the market for rheumatoid arthritis in 40 countries.”
The study of the effectiveness of the baricitinib included more than 300 patients.
“The results demonstrated marked improvements in joint pains and fatigue associated with the disease,” Wallace said.
A Phase III trial is in the planning phase.